ClinicalTrials.Veeva

Menu

Educational-Medical-Behavioral Treatment of Fecal Incontinence (FIX)

University of North Carolina (UNC) logo

University of North Carolina (UNC)

Status

Terminated

Conditions

Fecal Incontinence

Treatments

Drug: Laxatives or anti-diarrheals
Other: Protective pads or garments
Dietary Supplement: Fiber supplements
Behavioral: Daily diary
Behavioral: Pelvic floor muscle exercises
Behavioral: Tips on how to prevent fecal incontinence
Other: Education

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT01717456
R01HS018695 (U.S. AHRQ Grant/Contract)
11-1569

Details and patient eligibility

About

In previous studies at a university referral center the investigators demonstrated that a multicomponent conservative treatment for fecal incontinence was effective. The treatment combines patient education with medical management of diarrhea and constipation plus behavioral training. The purpose of this study is to determine whether this treatment is effective when delivered by home health care nurses to frail elderly patients.

Full description

Fecal incontinence (FI) affects 9% of U.S. adults and occurs weekly or more often in 2.7%. Prevalence increases with age reaching 15% by 70 years. FI has a devastating impact on quality of life and substantially increases caregiver burden when patients have comorbid conditions requiring caregiver assistance. The investigators propose an effectiveness trial whose overall goal is to determine whether a conservative intervention which has been shown to be effective in single-site studies will sustain its efficacy when disseminated to a home bound population by home health care nurses. The treatment includes patient education about the physiology of how continence is maintained, pelvic floor exercises, behavioral strategies for preventing FI, and use of fiber or nonprescription medication to treat diarrhea or constipation. To minimize drift when the treatment is disseminated to a large group of providers, patient education and other basic components of treatment are included in a printed training manual and are available to nurse providers on a website; however, nurse supervision to individualize treatment remains important. The study will be carried out in 8 counties in central North Carolina which are served by the University of North Carolina Home Health Care and Rex Home Health Care agencies (partners in this study). Nurses in these agencies will be randomly assigned to two groups. For the first two years all patients of the nurses in one group will receive the active intervention while all patients of nurses in the other group will receive usual care plus a training manual and symptom monitoring to control for expectancy. After two years, all patients in these home health care agencies will receive the active intervention. After excluding patients with severe cognitive impairment and those with stomas, the investigators estimate 252 - 340 patients with FI who are over age 50 will receive treatment (at least 189 in active treatment and 63 controls). Specific aims are (1) to show that the active treatment is more effective than the control treatment for improving FI severity, patient quality of life, and caregiver burden, and that improvements are maintained for at least 6 months; (2) to identify moderators of treatment effectiveness (candidate variables are cognitive status, mobility impairment, willingness of family caregiver to assist with treatment, anxiety, depression, age, and race); and (3) to explore whether successful treatment of FI reduces the risk of nursing home referral.

Enrollment

31 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Self-reported fecal incontinence at least once a month
  • Family caregiver available and willing to participate in treatment sessions and willing to assist patient with study procedures
  • Patients and caregivers willing to be interviewed by a research assistant in their home on three occasions
  • Onset of fecal incontinence more than 3 months previously (i.e., not transient fecal incontinence)

Exclusion criteria

  • Has a stoma or fecal incontinence status is unknown
  • Has fecal incontinence less than monthly
  • Severe cognitive impairment (response of 4 on OASIS question M1700)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

31 participants in 2 patient groups, including a placebo group

Educational-Medical-Behavioral
Active Comparator group
Description:
Educational-Medical-Behavioral intervention includes education, fiber supplements \[Metamucil 1-4 packets (3.4-13.6 g)/day\], laxatives or anti-diarrheals \[Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day\], pelvic floor muscle exercises \[100 10-second squeezes/day\], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments \[as needed\].
Treatment:
Dietary Supplement: Fiber supplements
Behavioral: Tips on how to prevent fecal incontinence
Behavioral: Pelvic floor muscle exercises
Behavioral: Daily diary
Other: Education
Other: Protective pads or garments
Drug: Laxatives or anti-diarrheals
Standard Care
Placebo Comparator group
Description:
Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day\], daily diary, and protective pads or garments \[as needed\].
Treatment:
Dietary Supplement: Fiber supplements
Behavioral: Daily diary
Other: Protective pads or garments

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems